Bangladeshi patients treated with stem cell therapy in city – Mumbai … – Mumbai Mirror

Bangladeshi activist and city-based medical centres collaborate to provide life-saving treatment for the three patients.

A Navi Mumbai-based treatment centre used stem cell therapy for the first time on three Bangladeshi patients suffering from an incurable muscular dystrophy.

The trio have been suffering from a rare disease called Duchenne Muscular Dystrophy, which causes progressive muscle degeneration, since birth. The disease limits the lifespan of the patient to just 30 years.

The doctors took stem cells from the patients bone marrow in the hip bone, processed it and injected it back into their bodies. The coordinator between the patients and the treating centre, Avantika Patil said, The patients are also undergoing physiotherapy and occupational therapy while we wait for the results of the procedure to show.

The treatment was made possible by the efforts of a Bangladeshi activist, Noor Khan, a Mumbai-based organisation, Meditourz, which worked in collaboration with a brain and spine institute from Navi Mumbai, NeuroGen.

It was NeuroGen which learnt about the three patients from an article in the international media and offered to treat their disease.

Of the three patients, the youngest, Shorab (8) has a mild disorder. This early medical intervention is expected to make his life less painful. However, the other two patients, Abdus (24) and Rahinul (14) are at a progressive stage.

Their father, Tofazzal Hossain, had even sought mercy killing from Bangladesh government for the duo as he could not afford the cost of their treatment. The travel arrangements were made in coordination with the Indian government. Free round-trip tickets were offered to six persons the patients and their caretakers who accompanied them to Mumbai from Kolkata, by Air India.

Visit link:
Bangladeshi patients treated with stem cell therapy in city - Mumbai ... - Mumbai Mirror

Durability of CAR T-cell therapy response may depend on … – Medical Xpress

April 4, 2017

Although most patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) experienced complete response after treatment with a type of CAR T-cell immunotherapy, pretreatment disease burden impacted the durability of the responses and long-term survival, according to data from a clinical trial presented here at the AACR Annual Meeting 2017, April 1-5.

"Adult patients with relapsed or refractory ALL have extremely poor outcomes, with the five-year survival rate being less than 10 percent. Therefore, there is a clear need to develop effective therapy for these patients," said Jae Park, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center (MSKCC) in New York.

"To this end, we and other groups have developed and tested CD19-specific CAR T-cell therapy [19-28z CAR T-cell therapy] and have reported encouraging results, with high initial complete response rates in patients with B-ALL. However, relapses are common, even after achieving seemingly deep remission, and severe toxicities have been observed in some patients," Park noted.

Park and colleagues, therefore, retrospectively analyzed data from a prospective clinical trial that tested 19-28z CAR T-cell therapy to identify patients who benefited the most from this therapy. All of the 51 adult patients in this trial had relapsed or refractory B-ALL after one or more conventional multiagent chemotherapy.

The researchers measured disease burden prior to CAR T-cell infusion in all patients and divided them into two cohorts those who had minimal residual disease (MRD) with less than 5 percent blast cells in bone marrow (20 patients), and those who had morphologic disease, with 5 percent or more blast cells in bone marrow (31 patients).

Complete response rates in the MRD cohort and morphologic disease cohort were 95 percent and 77 percent, respectively, which was not statistically different. After a median of 18 months of follow-up, median event-free survival and overall survival could not be computed for those in the MRD cohort (because most patients were still disease-free and alive), but they were 6.3 months and 17 months, respectively, for those in the morphologic disease cohort.

The study also found that long-term survival did not improve for patients in either cohort by having a hematopoietic stem cell transplant (HSCT) after CAR T-cell therapy.

"While more patients and longer follow-up will be needed to adequately address the significance of HSTC, the result of this analysis raises a question as to whether 19-28z CAR therapy can be considered as a definitive, curative therapy rather than a bridge to stem cell transplant, at least in a subset of patients," Park noted.

"Our data suggest that incorporation of 19-28z CAR T cells at the time of MRD following first-line chemotherapy will maximize the durability of CAR T-cell mediated remissions and survival and can potentially spare these high-risk patients from HSCT, rather than waiting until they relapse morphologically and then trying CAR T-cell therapy when it is less likely to achieve a durable long-term outcome," Park added.

Patients from the MRD cohort fared well in terms of side effects as well, compared with those in the morphologic disease cohort. Two of the major side effects associated with CAR T cells, cytokine release syndrome (CRS) and neurotoxicity, occurred in 42 percent and 58 percent of the patients, respectively, in the morphologic disease cohort, compared with 5 percent and 15 percent, respectively, in those from the MRD cohort. No case of cerebral edema was observed in either cohort of this study, Park noted.

A limitation of the study is that this is a retrospective analysis and the findings will need to be validated prospectively, Park said. Further, the analysis on the impact of post-CAR allogeneic HSCT was limited by a relatively small sample size in each cohort as the study was not designed to specifically answer or address that question.

Explore further: Five-year survival rate for nivolumab-treated advanced lung cancer patients much higher than historical rate

Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data ...

Among patients with metastatic triple-negative breast cancer (TNBC) who were treated with the anti-PD-L1 cancer immunotherapy atezolizumab (Tecentriq), those who responded to the medicine lived significantly longer (overall ...

Immune cellular therapy is a promising new area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and ...

(HealthDay)For patients 40 years of age with Philadelphia (Ph)-negative acute lymphoblastic leukemia (ALL), hematopoietic stem-cell transplantation (HSCT) in first remission is associated with lower cumulative incidence ...

A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard chemotherapy for treatment of advanced acute lymphoblastic leukemia (ALL). ...

A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising ...

Women with a healthy body mass index (BMI) may be at risk of developing breast cancer because of enlarged fat cells in their breast tissue that trigger an inflammatory process, according to a new study from Weill Cornell ...

Duke Cancer Institute scientists have described a previously unknown series of steps that cells undergo when stressed, adding crucial information to the understanding of DNA damage that is at the heart of research into aging ...

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment.

Smoking by either parent helps promote genetic deletions in children that are associated with the development and progression of the most common type of childhood cancer, according to research headed by UC San Francisco. ...

Multiple myeloma is a cancer of the plasma cells, which are white blood cells produced in bone marrow that churn out antibodies to help fight infection. When plasma cells become cancerous, they produce abnormal proteins, ...

A team led by researchers from the Stanford University School of Medicine has demonstrated a way to diagnose cancer without resorting to surgery, raising the possibility of far fewer biopsies.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Originally posted here:
Durability of CAR T-cell therapy response may depend on ... - Medical Xpress

Researchers will use stem cell therapy to grow heart muscle in new study – Cardiovascular Business

The U.S. Food and Drug Administration (FDA) has approved a new study that will test the efficacy of a stem cell technique used on children suffering from congenital heart disease.

The study is being hosted by Boston Childrens Hospital and Mesoblast Limited, a regenerative medicine company based in Australia. Their 24-patient trial will test the efficacy of Mesoblasts proprietary allogenic mesenchymal precursor cells (MPCs) in a corrective heart surgery on children under the age of 5 that suffer from hypoplastic left heart syndrome (HLHS), according to an April 3 press release.

The new technique is designed to save more patients with HLHS because current treatment is not always effective. Right now physicians generally perform a single, ventricle palliation, which results in the patient using only the right ventricle to the support the hearts entire circulation. However, the treatment is usually only a temporary fix because the right ventricle will eventually tire out, putting the patient at an increased risk for sudden cardiac arrest.

In the randomized, controlled trial, researchers will inject Mesoblasts MPC-150-IM into the left ventricle during surgical recruitment procedures, which should improve ventricular mass and function and ultimately lead to a higher likelihood of biventricular conversion.

The objective of combining Boston Children Hospitals expertise in pioneering surgical approaches to treating hypoplastic heart syndrome with the regenerative potential of our lead cardiovascular product, MPC-150-IM, is to develop a highly innovative treatment for this complex congenital condition as well as other serious and life-threatening cardiac diseases in children, said Kenneth Brow, the senior clinical development executive and head of cardiovascular diseases at Mesoblast, in a statement.

See the original post here:
Researchers will use stem cell therapy to grow heart muscle in new study - Cardiovascular Business

Stem-cell therapy is poised to disrupt the Tommy John epidemic in baseball – Quartz


Quartz
Stem-cell therapy is poised to disrupt the Tommy John epidemic in baseball
Quartz
For about half a decade, it's been something of an open secret in baseball that playerspitchers especiallyregularly undergo stem-cell therapy to stave off surgeries and lost playing time. It's a cutting-edge medical procedure, done by everyone from ...

Read this article:
Stem-cell therapy is poised to disrupt the Tommy John epidemic in baseball - Quartz

Stem cells offer hope for autism – CNN

It wasn't always so. Just a couple years ago, Ryleigh, 11, was scared of her sister when she'd throw tantrums and screaming fits.

"She would've fought and kicked," Ryleigh says, noting that it wouldn't have been possible to sit like this next to Gracie.

Gracie, 7, interrupts: "I don't even remember it."

"We do," says her mother, Gina Gregory.

Gracie has autism, a condition that affected nearly every aspect of her family's life after she was diagnosed at 2. But a new study is offering hope for the Gregorys and families like them.

The results were impressive: More than two-thirds of the children showed reported improvements. A larger second trial is underway, one its researchers hope will lead to long-term treatment for children with autism.

But for the Gregorys, the change in their daughter has been monumental.

Gone are the days of Gracie throwing fits in long lines at Disney World or during dinner at restaurants. When a tantrum intruded on family outings, her mom and dad wished they had T-shirts that said "My kid has autism" to ward off judgmental stares.

During autism therapy sessions, Gracie would kick, scream, spit and hit at her occupational therapist. "It was horrible to try to get her to sit there," her mother says.

Even just brushing her teeth or combing her hair could set her off.

Gracie, then 5, was on the mild to moderate autism scale, but her parents say the disorder consumed about 75% of their daily routine. After her participation in the study, that figure has been reduced to a mere 10%.

On a scale of 1 to 10, they rate her improvement around an 8 or 9; it's been that dramatic. She's even begun attending a "regular" school and thriving there, something her parents never thought possible. She'd been in various specialized school programs, and nothing was the proper fit.

Are Gracie's changes a result of the cord blood transfusion stimulating her brain? Or did her brain just mature as she got older? Could it be that her parents were subconsciously determined to magnify her improvements, given all their family had been through?

Those are questions the Gregorys still ask. But they do know that their daughter's transformation appeared to begin about six months after her transfusion in January 2015 and has continued ever since.

Her father's favorite adjustment is her newfound affection. Instead of shunning hugs, she now welcomes an embrace.

"We will say we don't think it's cured her. You still see some of the small idiosyncrasies that she does have," says her father, Wade Gregory. "But again, I think it's supercharged her learning curve. It's pushed her to do things she normally wouldn't do."

Her mother adds, "She got better, and we're just thankful for that -- whether it be the stem cells or not. We're just thankful for what changes have happened."

Each unit is designated by labels with specially designed adhesive to withstand extremely cold temperatures for decades. There are 14 cord blood freezers in all.

It is the cord blood in those freezers -- stored or donated by parents in case a serious illness develops -- that's at the cutting edge of this research.

About 30% never learn to speak, and many children even with early behavioral interventions still struggle to adapt. There also are no FDA-approved medications that improve the core symptoms of autism.

"I was very interested in collaborating with people here at Duke who could offer medical approaches that could enhance neuroplasticity, or the brain's ability to respond to treatment," Dawson says.

"We've been able to show that with some of these diseases, a cord transplant rescues them from death and also improves their neurologic outcome," she says.

She began wondering: Could cord blood help other children?

About a decade ago, her laboratory began clinical tests of children with cerebral palsy whose parents had banked their cord blood. Again, they saw positive results. And in some of those children who had autistic tendencies, they saw autistic symptoms improve. Another spark went off: What if they tested cord blood specifically for autism?

The safety trial began a little over a year and a half ago. Not only did it find cord blood to be safe, but 70% of the 25 children, age 2 to 6, had behavioral improvements as described by their parents and tracked by the Duke researchers. The research is largely funded by a $40 million donation from the Marcus Foundation, a nonprofit created by Home Depot co-founder Bernie Marcus.

The children traveled to Duke three times over the course of a year. They underwent a series of evaluations such as autism assessments, MRIs and EEGs to track their brain activity. On the first trip, the children received the cord blood infusion along with the intense evaluations. Each child received 1 billion to 2 billion cells, given through an IV in their arms or legs. At six months and then a year later, the children returned for more tests and observations.

"Some children, who were not speaking very much, had big increases in their vocabulary and their functional speech," Kurtzberg says. "Many children were able to attend to play and have meaningful communication in a way that they weren't before. Some children had less repetitive behaviors than they did when they came onto the study."

Adds Dawson, "The study was very encouraging. We did see positive results. However, it did not have a comparison group, which is very important in establishing whether a treatment is actually effective."

Both researchers can't stress that enough: that although they're cautiously optimistic about the results, they want the science to play out. They are now in the midst of the definitive trial on whether cord blood can treat autism -- a double-blind, placebo-controlled trial involving 165 autistic children, ranging in age from 2 to 8. The FDA has oversight of the study.

During the phase II study, the children on their first visit receive a cord blood infusion -- either their own or from a donor -- or they get a placebo. They also undergo a battery of assessment tests and brain monitoring.

On their second visit six months later, the children receive a second infusion with whatever preparation they did not receive the first time and undergo more evaluations. The order of the infusions is not known. Researchers will monitor them for the next year for any sign of behavioral improvements.

It's known as a crossover trial, in which each subject gets the treatment and the placebo but in a different order. Researchers say it would have been nearly impossible to find participants if parents knew that their children might not receive an infusion.

How groundbreaking would it be if the trial shows similar results to the safety study?

"If we can show that receiving an infusion of cord blood is more effective for improving social behavior than the placebo," Dawson says, "then this will be game-changing."

Kurtzberg adds, "We'll be extraordinarily encouraged if the second trial shows that the cells benefit children when the placebo does not. We will consider that a breakthrough."

Both researchers were shaped early in life by the struggles families face raising autistic children. As a teen, Dawson babysat twins with autism who lived across the street. "It was just an inspiration to devote my career to improving the lives of people with autism," she says.

Kurtzberg was similarly affected. When she was a junior in college, she would visit a girl with severe autism and play with her as a means of behavioral intervention. "The family still writes to me," she says.

It is for this reason -- their longtime devotion to families raising children with autism -- that both issue a heap of caution. Although they're excited about the results of the first study, Kurtzberg says, "we don't want to mislead people and claim it's working before we have definitive proof."

Adds Dawson, "It's important for parents who might hear about cord blood as a potential treatment for autism to know that we are working very hard to know the answer to that question. We aren't there yet."

Kurtzberg has a hypothesis about what may be happening: that certain immune cells within the cord blood are crossing the blood-brain barrier and altering brain connectivity while also suppressing inflammation, which may exist with autism.

"I feel more confident now because of our (cerebral palsy) study, which preceded this study and does show benefits," Kurtzberg says.

"One has to be very careful when interpreting results that haven't come from properly controlled, double-blind studies," he said. "All I can say is that it would be wonderful if this treatment was effective, but one has to be very cautious before reaching any conclusions."

Even without a placebo effect, he says, many factors could have resulted in an improved outcome in the first study: The growing children could have acquired skills simply through maturation, possibly enhanced by occupational therapy, and their parents may have clung to positive gains, creating a biased outcome.

Kriegstein of UCSF also wonders whether cord blood is really stimulating cells in the brain and creating new connections. "There are so many unanswered questions about what might be going on here, it becomes very difficult to evaluate the proposed mechanism," he said.

"The question remains: How do these cells injected intravenously wind up in the brain, how do they target the appropriate brain regions, and what are they doing that could improve brain function?"

An 8-year-old boy with autism sits at a table in a room within Duke's Center for Autism and Brain Development. Clinical research specialist Michelle Green watches from behind a two-way mirror. Two cameras in the room feed computer monitors, allowing her to further analyze his behavior.

Dr. Lauren Franz, a clinician, works with the boy in the room.

"What kind of things make you feel threatened or anxious?" she asks.

"Like when I'm done with a test," the boy says.

"How does it feel when you're frightened or anxious? How does that feel?"

"Like pretty weird," he says.

The boy is participating in the second trial, and he's returned for his six-month assessment and second infusion. Researchers don't know which infusion he received first: the cord blood or the placebo.

But they track, record and monitor the slightest of details. Although it might seem like an innocuous conversation, researchers will compare the results with those of his first visit and any follow-ups. Was he able to sit still at the table before? Could he articulate his thoughts? Did he talk before the study? Has he improved?

At the Gregorys' home in Florida, Gracie's parents remember when she went through those same tests. The best investment they ever made, they say, was the $2,000 spent on banking her cord blood. At the time, it was just a precaution; her autism diagnosis didn't come until three months after her second birthday.

They know the desperation of families raising a child with autism -- of longing for their daughter to have a shot of normalcy in life. "You can't quantify it. You can't measure it. You want to see your child succeed," her father says.

Mom and Dad recently watched old home videos, of Gracie singing inaudibly, of her covering her ears when "Happy Birthday" was sung for her third birthday, of showing no emotion on Christmas when she was 2. "I forgot how bad it was," her mother says.

They hope the current study leads to similar successes -- and results in breakthrough treatment for autistic children everywhere.

Visit link:
Stem cells offer hope for autism - CNN

Stem cell treatment begins for dystrophy patients from Bangladesh … – Daily News & Analysis

Three Bangladeshis suffering from a highly debilitating muscular dystrophy, who arrived in Mumbai on Sunday have begun their treatment at a Navi Mumbai spine clinic.

Abdus, Rahinul and Shorab aged 24, 14 and 8 respectively were diagnosed with this crippling disease at the time of their birth.

They arrived on Sunday evening and we started the treatment on Monday, said Avantika Patil, spokesperson NeuroGen Brain and Spine Institute in Seawoods, Navi Mumbai, who is treating them for free.

They are undergoing an autologous bone marrow derived stem cell treatment. Stem cells are taken from the bone marrow in their hip bone, treated in our lab and then injected into to the patients again. We will provide a combination of stem cell therapy and neuro-rehabilitation which will also includes yoga and speech therapy sessions, Patil explained.

While the hospital is not willing to say what kind of progress can be expected in these particular cases, they revealed that in one case, a bed-ridden patient was able to walk slowly after six years of treatment.

In January, fruit seller Tofazzal Hossain sparked a rare debate about euthanasia in conservative Bangladesh in January when he pleaded with the authorities to allow his grandson and two sons to die.

See the original post:
Stem cell treatment begins for dystrophy patients from Bangladesh ... - Daily News & Analysis

Recent Study Shows Stem Cell Research Helping Children Deal … – NBC 6 South Florida

NEWSLETTERS Receive the latest local updates in your inbox

NBC 6's Julia Bagg tells us about the Duke University study showing stem cell research playing a role in possibly helping those kids. (Published 5 hours ago)

A first of its kind study from Duke University is targeting autism with the goal being to see if stem cells could be used to help treat children dealing with the disorder.

Researchers used umbilical cord blood infusions to help ease autism symptoms in children. They found that using the youngsters own rare stem cells resulted in significant improvements in their behavior.

According to the Centers for Disease Control and Prevention, as many as one in 45 American children has been diagnosed with an autism spectrum disorder. Symptoms vary from mild social awkwardness to serious mental handicap, debilitating repetitive behaviors, and an inability to communicate.

Theres no cure, but researchers hope their findings could lead to long-term treatment. Skeptics point out there are many unanswered questions in this study, but now a second trial is underway.

Published 5 hours ago | Updated 4 hours ago

Read more:
Recent Study Shows Stem Cell Research Helping Children Deal ... - NBC 6 South Florida

Frequency Therapeutics to Present at the 14th Stem Cell Research … – Yahoo Finance

WOBURN, Mass.--(BUSINESS WIRE)--

Frequency Therapeutics, a company spearheading the movement to restore hearing by harnessing the regenerative potential of progenitor cells in the body, today announced that Chris Loose, Ph.D., the Companys Co-founder and Chief Scientific Officer, will be presenting at the 14th Stem Cell Research and Regenerative Medicine Conference. The presentation titled, Progenitor Cell Activation - an Enabling Technology for In-Situ Tissue Regeneration, will look to explore the companys proprietary Progenitor Cell Activation (PCA) platform, founded on recent discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard. PCA is leading to a new class of drugs that regenerate healthy tissue within the body. The presentation will take place on Wednesday, April 5 at 4:50 p.m. The conference is being held from April 5 to 6 in Boston, MA.

The biology, chemistry and regenerative properties behind our PCA platform is quite exciting and has the potential to yield a whole new category of disease-modifying therapeutics for a wide range of degenerative conditions, said Dr. Loose. Our lead program is focused on the over 360 million people worldwide who suffer from hearing impairment, with no effective therapeutic solutions currently available. By targeting cellular regeneration within the inner ear to restore healthy tissue and reverse hearing loss, we look to develop a direct therapeutic approach through a locally applied drug without the need for surgical interventions.

Chris has provided exceptional leadership in translating the vision of our founders, Bob Langer and Jeff Karp, into a successful product development organization, said David Lucchino, President, Co-founder and CEO of Frequency. This presentation exemplifies the core of the research and development Frequency is performing with our PCA platform, and addresses our intent of advancing a first-in-class therapeutic option for chronic hearing loss.

ABOUT PROGENITOR CELL ACTIVATION (PCA) Frequencys precise and controlled approach transiently causes Lgr5+ progenitor cells to divide and differentiate, much like what is seen in naturally regenerating tissues such as the skin and intestine. Frequency activates stemness through mimicking signals provided by neighboring cells (the stem cell niche) with small molecules, and this proprietary approach is known as the Progenitor Cell Activation (PCA) platform. Frequency believes that PCA has the potential to yield a whole new category of disease-modifying therapeutics for a wide range of degenerative conditions. To fuel its drug discovery programs, Frequency is leveraging a PCA screening platform using primary human cells, including cochlear progenitor cells and adult human progenitor cells from the GI tract. Frequencys initial focus is on chronic noise induced hearing loss. Other potential applications include skin disorders, gastrointestinal diseases, and diabetes.

ABOUT FREQUENCY THERAPEUTICS Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. http://www.frequencytx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170405005401/en/

Continue reading here:
Frequency Therapeutics to Present at the 14th Stem Cell Research ... - Yahoo Finance

Artificial Thymus Can Produce Cancer-fighting T Cells From Blood Stem Cells – Bioscience Technology

UCLA researchers have created a new system to produce human T cells, the white blood cells that fight against disease-causing intruders in the body. The system could be utilized to engineer T cells to find and attack cancer cells, which means it could be an important step toward generating a readily available supply of T cells for treating many different types of cancer.

The preclinical study, published in the journal Nature Methods, was led by senior authors Dr. Gay Crooks, a professor of pathology and laboratory medicine and of pediatrics and co-director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and Amelie Montel-Hagen, an associate project scientist in Crooks lab.

The thymus sits in the front of the heart and plays a central role in the immune system. It uses blood stem cells to make T cells, which help the body fight infections and have the ability to eliminate cancer cells. However, as people age or become ill, the thymus isnt as efficient at making T cells.

T cells generated in the thymus acquire specialized molecules, called receptors, on their surface, and those receptors help T cells seek out and destroy virus-infected cells or cancer cells. Leveraging that process has emerged as a promising area of cancer research: Scientists have found that arming large numbers of T cells with specific cancer-finding receptors a method known as adoptive T cell immunotherapy has shown remarkable results in clinical trials.

Adoptive T cell immunotherapy typically involves collecting T cells from people who have cancer, engineering them in the lab with a cancer-finding receptor and transfusing the cells back into the patient.

However, adoptive T cell immunotherapy treatments can be time-consuming, and people with cancer might not have enough T cells for the approach to work, according to Dr. Christopher Seet, the studys first author and a clinical instructor who treats cancer patients in the division of hematology-oncology at UCLA.

Since adoptive T cell immunotherapy was first used clinically in 2006, scientists have recognized that it would be more efficient to create a readily available supply of T cells from donated blood cells or from pluripotent stem cells, which can create any cell type in the body. The challenge with that strategy would be that T cells created using this approach would carry receptors that are not matched to each individual patient, which could ultimately cause the patients body to reject the transplanted cells or could cause the T cells to target healthy tissue in addition to cancer cells.

We know that the key to creating a consistent and safe supply of cancer-fighting T cells would be to control the process in a way that deactivates all T cell receptors in the transplanted cells, except for the cancer-fighting receptors, Crooks said.

The UCLA team used a new combination of ingredients to create structures called artificial thymic organoids that, like the thymus, have the ability to produce T cells from blood stem cells. The scientists found that mature T cells created in the artificial thymic organoids carried a diverse range of T cell receptors and worked similarly to the T cells that a normal thymus produces.

Next, the team tested whether artificial thymic organoids could produce the specialized T cells with cancer-fighting T cell receptors. When they inserted a gene that delivers a cancer-fighting receptor to the blood stem cells, they found that the thymic organoids produced large numbers of cancer-specific T cells, and that all other T cell receptors were turned off. The results suggest that the cells could potentially be used to fight cancer without the risk of T cells attacking healthy tissue.

Montel-Hagen said the artificial thymic organoid can easily be reproduced by other scientists who study T cell development. The UCLA researchers now are looking into using the system with pluripotent stem cells, which could produce a consistent supply of cancer-fighting T cells for patients in need of immediate life-saving treatment.

Kite Pharma holds a license to the artificial thymic organoid method, which is patented by the Regents of the University of California.

Read more:
Artificial Thymus Can Produce Cancer-fighting T Cells From Blood Stem Cells - Bioscience Technology

Autologous Cell Therapy Market 2024; Debate over Ethics of Embryonic Stem Cells Creates Impediment – MilTech

Albany, NY (SBWIRE) 04/03/2017 The leading players operating in the global autologous cell therapy market are Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc. These companies are expected to focus on mergers and acquisitions to enter local markets, observes Transparency Market Research. Furthermore, efforts to establish subsidiaries and manufacturing centers in emerging economies are also expected to make the global market exceptionally competitive in the coming few years.

According to the research report, the global autologous cell therapy market is expected to be worth US$23.7 bn by the end of 2024 as compared to US$3.8 bn in 2015. During the forecast period of 2016 and 2024, the global market is estimated to exhibit a CAGR of 21.9%.

Obtain Report Details: http://www.transparencymarketresearch.com/autologus-cell-therapy-market.html

Grants to Continue R&D Keep North America in the Lead

On the basis of source, the global market is segmented into bone marrow and epidermis. Of these, the bone marrow segment is expected to prosper as compared to the other segment. By the end of 2024, the bone marrow segment is expected to reach a valuation of US$12.0 bn. Known as the hub of stem cell, the bone marrow segment is expected to grow against the backdrop of increasing number of bone marrow-based products being manufactured by the pharmaceutical industry. Furthermore, the extensive research and development activities for bone marrow-based stem cells is also expected to boost the growth of the market.

In terms of geography, the global autologous market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these North America is expected to dominate the global market in the coming years. The North America autologous Cell therapy market was valued at US$2.1 bn in 2015. Provision for grants from organizations such as CIRM, National Institutes of Health (NIH), and New York Stem Cell Science are expected to keep North America in the forefront in the coming few years.

High Prevalence of Cancer Triggers Demand for Autologous Cell Therapy

The America Cancer Society states about a million people in the U.S. alone are diagnosed with various types of cancer with each passing years. The World Health Organization states that there will be a 30% rise in the number of cancer cases in the next decades. Furthermore, drastically changing lifestyles that are defined by the poor dietary choices and sedentary living are also expected to contribute the soaring number of cancer cases across the globe. Statistics shared by International Agency for Research on Cancer (IARC) and WHO stated that the occurrence of cancer has been on the steady rise amongst the geriatric population. Furthermore, about 60% of the worlds new cancer cases are registered in developing regions of Asia, Africa, and Central America. All of these factors have triggered a huge demand for autologous cell therapy for treating cancer and managing the disease.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=715

Debate over Ethics of Embryonic Stem Cells Creates Impediment

The heated debate over ethical issues of the killing of embryos after extraction of cells is the toughest challenge of the global autologous cell therapy market. Thus, the restriction on research and development activities pertaining to embryonic stems cells is anticipated to hamper the growth of the overall market. Furthermore, lack of reimbursement policies for those seeking cell therapy along with the high cost of treatment is also expected to restrict the scope for growth for the overall market.

This review is based on Transparency Market Researchs review, titled Autologous Cell Therapy Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 2024.

Contact us: Transparency Market Research 90 State Street, Suite 700, Albany NY 12207 United States Tel: +1-518-618-1030 USA Canada Toll Free 866-552-3453 Email:sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/

Read the original post:
Autologous Cell Therapy Market 2024; Debate over Ethics of Embryonic Stem Cells Creates Impediment - MilTech